Theragenics to Report Second Quarter 2013 Financial Results on August 8, 2013

Before you go, we thought you'd like these...
Before you go close icon

Theragenics to Report Second Quarter 2013 Financial Results on August 8, 2013

BUFORD, Ga.--(BUSINESS WIRE)-- Theragenics Corporation® (NYS: TGX) expects to release second quarter 2013 financial results before the market opens on August 8, 2013. As a result of the merger agreement with Juniper Investment Company, LLC, announced August 5, 2013, management of Theragenics will not be hosting a conference call.

Theragenics Corporation (NYS: TGX) operates two business segments: its surgical products business and its brachytherapy seed business. The surgical products business (,, manufactures and distributes wound closure, vascular access, and specialty needle products. Wound closure products include sutures, needles and other surgical products. Vascular access includes introducers, guidewires and related products. Specialty needles include coaxial, biopsy, spinal and disposable veress needles, access trocars, implanters, introducer products, and other needle-based products. The surgical products segment serves a number of markets and applications, including, among other areas, interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery. Theragenics' brachytherapy business manufactures, custom loads, distributes and markets "seeds" used primarily in the minimally invasive treatment of localized prostate cancer. The Company's brachytherapy product line ( includes its palladium-103 TheraSeed® device and its iodine-125 AgX100® device. The terms "Company," "we," "us," or "our" mean Theragenics Corporation and all entities included in our consolidated financial statements. For additional information, call our Investor Relations Department at (800) 998-8479 or visit

Additional Information and Where to Find It

In connection with the proposed transaction, the Company will file a proxy statement with the SEC. INVESTORS ARE STRONGLY ADVISED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ON THE PROPOSED TRANSACTION. Investors may obtain free of charge the proxy statement (when available) and other relevant documents filed with the SEC with respect to the proposed transaction at the SEC's website at In addition, the proxy statement (when available) and such other documents may be obtained free of charge by directing a request to Theragenics Corporation, 5203 Bristol Industrial Way, Buford, Georgia 30518, Attention: Investor Relations Department, (800) 998-8479.

The Company and its directors, executive officers and certain other members of its management and employees may be deemed to be participants in the solicitation of proxies from its stockholders in connection with the proposed merger. Information regarding the interests of such directors and executive officers is included in the Company's proxy statement for its 2013 Annual Meeting of Stockholders filed with the SEC on April 1, 2013, and information concerning all of the Company's participants in the solicitation will be included in the proxy statement related to the proposed merger when it becomes available.

Theragenics Corporation
Frank J. Tarallo, 800-998-8479 or 770-271-0233
CFO & Treasurer
Lisa Rassel, 800-998-8479 or 770-271-0233
Investor Relations Manager

KEYWORDS:   United States  North America  Georgia  New York


The article Theragenics to Report Second Quarter 2013 Financial Results on August 8, 2013 originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading